1. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective.
- Author
-
Bernhardt MB, Lindsay H, Allen-Rhoades W, and Foster JH
- Subjects
- Child, Government Regulation, Humans, United States, United States Food and Drug Administration, Drug-Related Side Effects and Adverse Reactions prevention & control, Legislation, Drug standards, Neoplasms drug therapy, Pharmaceutical Preparations administration & dosage, Product Surveillance, Postmarketing methods
- Abstract
The scarcity of adequate pediatric drug labeling information has long been problematic in the pediatric population, which may place children at risk for adverse drug effects. The ontogeny of infants, children, and adolescents over the course of the first two decades of life pose complex pharmacokinetic, dosing, administration, effectiveness, and toxicity-related questions that require specific investigation. Here, we review the history that led to the passage of the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA), and provide commentary on issues relevant to pediatric oncology now and in the future., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF